Fig. 5
From: Wild-type IDH1 inhibition enhances chemotherapy response in melanoma
Targeting IDH1 sensitizes melanoma cells to conventional anti-melanoma cytotoxic therapy. A Silencing IDH1 followed by treatment with TMZ for 5 days under high glucose (25 mM) and B low glucose concentrations (2.5 mM) in the A375 cell line. IC50 values are provided. C Cell viability of the A375 cell line treated with the indicated doses of TMZ. IC50 values are provided. D Cell viability of the A375 cell line treated with indicated doses of AG-120. IC50 values are provided. E Drug sensitivity in the A375 cell line under low glucose concentrations and with varying doses of TMZ and AG-120 cultured for 5 days. IC50 is provided. F Drug matrix heatmap 5 × 8 (AG-120 and TMZ) grid showing percent viability and Bliss Independence scores in A375 cells cultured under 2.5 mM glucose for 5 days. Positive values reflect synergy and appear blue on the heatmap. All treatments with AG-120 were carried out under low glucose and low Mg2+ concentrations